Bioventus (BVS) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bioventus (BVS) has outperformed QuidelOrtho (QDEL) over the past year, gaining 92.0% versus a loss of 55.6%. Over five years, BVS leads with a -6.4% price change compared with -90.4% for QDEL. Bioventus is the larger company by market cap ($872.3 million vs $844.2 million), about 1.0 times the size.
On valuation, QuidelOrtho trades at a lower forward P/E (8.5x vs 13.9x for Bioventus).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | QDEL |
|---|---|---|
| Share price | $12.77 | $12.31 |
| Market cap | $872.26M | $844.16M |
| 1-day change | -2.52% | -2.07% |
| YTD return | +71.64% | -56.90% |
| 1-year return | +92.03% | -55.58% |
| 5-year return | -6.38% | -90.40% |
| P/E ratio (TTM) | 16.80 | — |
| Forward P/E | 13.88 | 8.54 |
| EPS (TTM) | $0.76 | $-15.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.89 | $35.58 |
| 52-week low | $6.37 | $9.92 |
| Distance from 52-week high | -19.65% | -65.40% |
| Analyst consensus | none | hold |
| Avg. price target upside | +37.82% | +19.17% |
| Average volume | 623.67K | 1.47M |
| Shares outstanding | 68.31M | 68.58M |
| Employees | 950 | 6,500 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BVS has outperformed QDEL by 147.6 percentage points over the past year.
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Healthcare · Medical Devices · 950 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Healthcare · Medical Devices · 6,500 employees
BVS vs QDEL FAQ
Which is bigger, Bioventus or QuidelOrtho?
Bioventus (BVS) is larger, with a market capitalization of $872.26M compared with $844.16M for QuidelOrtho (QDEL).
Which stock has performed better over the past year, BVS or QDEL?
BVS returned +92.03% over the past 12 months, compared with -55.58% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Bioventus and QuidelOrtho in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.